Abstracts tagged "Outcome measures"

Abstract Number: 2315 • 2017 ACR/ARHP Annual Meeting
Symptoms of Depression and Anxiety in Children with JIA: Relation to Other Domains of Health Related Quality of Life
Michael Miller¹, Yufan Yan² and George Lales³, ¹Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is associated with symptoms of anxiety and depression. We studied these symptoms and other health related quality of life (HRQOL)…
Abstract Number: 235 • 2017 ACR/ARHP Annual Meeting
MRI in Rheumatoid Arthritis: Does Quantifying the Number of Erosive Lesions Improve Detection of Subtle Erosive Progression Compared to the Omeract RA MRI Scoring System?
Ulf Sundin¹, Anna-Birgitte Aga², Tore K Kvien³, Siri Lillegraven⁴ and Espen A. Haavardsholm⁴, ¹*Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Early detection of erosive progression is an important application of MRI in RA. For research purposes the OMERACT Rheumatoid Arthritis MRI Scoring system (RAMRIS)…
Abstract Number: 2525 • 2017 ACR/ARHP Annual Meeting
Influence of Cardiovascular Comorbidity on Achieving Therapeutic Goals: A Comparative Study between Recent-Onset Psoriatic Arthritis and Established Disease
Rubén Queiro¹ and Juan D. Cañete², ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Some cardiovascular risk factors (CVRF) have been associated with a lower probability of achieving a good therapeutic response in PsA1. However, the reason for…
Abstract Number: 338 • 2017 ACR/ARHP Annual Meeting
Measurement Properties of Paindetect, a Neuropathic Pain Screening Tool, for Evaluating Pain Phenotype in Patients with Rheumatoid Arthritis: Developing Neuropathic Pain Scale As a Measure of Treatment Outcome By Applying Rasch Analysis
Yong Gil Hwang¹, Lei Zhu², Ajay Wasan³ and Larry W. Moreland¹, ¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Departments of Anesthesiology and Psychiatry, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Ongoing pain state in rheumatoid arthritis (RA) often persists after the resolution of inflammation, indicating the transition between the acute inflammatory pain and post-inflammatory…
Abstract Number: 2536 • 2017 ACR/ARHP Annual Meeting
Comparison of Quality-of-Life, Function and Psoriasis Measures in Minimal Disease Activity and DAS28 States in Routine Care of Patients with Psoriatic Arthritis
Catherine Hughes, Nora Ng, Toby Garrood and Bruce Kirkham, Rheumatology, Guy's & St Thomas NHS Foundation Trust, London, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) often occurs with skin psoriasis (PsO). Disease activity can be measured using several tools including Minimal Disease Activity (MDA/VLMDA) or 28…
Abstract Number: 1079 • 2017 ACR/ARHP Annual Meeting
Treat to Target Adherence Measurement Tool Performance in Rheumatoid Arthritis
Rodrigo Garcia Salinas¹, Sebastian Magri² and Facundo Salvatori³, ¹Section of Rheumatology, Hospital Italiano de La Plata, Buenos Aires, Argentina, La Plata, Argentina, ²Section of Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina, ³Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: The purpose of the T2T approach in RA is to achieve remission or LDA according to results from objective activity measurements. This strategy has…
Abstract Number: 2547 • 2017 ACR/ARHP Annual Meeting
the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort
Leonieke van Mens¹, Arno van Kuijk², Dominique Baeten¹ and Laura C Coates³, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³LIRMM, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recommendations on psoriatic arthritis (PsA) state that the target of treatment should be remission or inactive disease with an alternative target of minimal or…
Abstract Number: 1238 • 2017 ACR/ARHP Annual Meeting
The Development of the Lupus Foundation of America—Rapid Evaluation of Activity in Lupus (LFA-REAL™) Patient-Reported Outcome (PRO) to Evaluate Lupus Disease Activity
Anca Askanase¹, Samantha Nguyen², Miya Okado², Nancy Leidy³ and Joan T. Merrill⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Evidera, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The LFA REALTM is designed as two complimentary disease activity measures in order to integrate clinician and patient input. The current report updates progress…
Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Laura C Coates¹, Proton Rahman², Eliofotisti Psaradellis³, Emmanouil Rampakakis³, Brendan Osborne⁴, Allen J Lehman⁵ and Francois Nantel⁴, ¹LIRMM, University of Leeds, Leeds, United Kingdom, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵Janssen Inc., Toronto, ON, Canada
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…
Abstract Number: 1293 • 2017 ACR/ARHP Annual Meeting
Indications for Cesarean Delivery in Systemic Lupus Erythematosus Pregnancies
Evelyne Vinet¹, Paul R. Fortin², Stéphanie Roberge³, Emmanuel Bujold⁴ and Nils Chaillet⁵, ¹Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ³Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada, ⁴Reproduction, mother and youth health, Centre Hospitalier de l'Université Laval (CHUL), Québec, QC, Canada, ⁵Département d’obstétrique et gynécologie et département de Médecine de famille et médecine d’urgence, Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Pregnant SLE women are at increased risk of cesarean delivery compared to pregnant women from the general population. Yet, to date, no one has…
Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Maria Laura Acosta Felquer¹, Musaab Elmamoun², Agnes Szentpetery^3,4, Phil Gallagher⁵, Oliver FitzGerald⁶ and Enrique R. Soriano⁷, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ³Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁶St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ⁷Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…
Abstract Number: 1356 • 2017 ACR/ARHP Annual Meeting
Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Aleid C. Boer¹, Annelies Boonen² and Annette H.M. van der Helm-van Mil³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated-protein antibodies (ACPA)-positive rheumatoid arthritis (RA) is considered as more severe than ACPA-negative RA, because of its association with joint destruction. Clinically relevant joint…
Abstract Number: 2781 • 2017 ACR/ARHP Annual Meeting
Assessing RA Disease Activity with Promis Measures Using Smartphone Technology
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health information technology has enabled efficient measurement of PROs using Computer Adaptive Testing (CAT) methods, which have been shown to minimize missing data and…
Abstract Number: 1384 • 2017 ACR/ARHP Annual Meeting
Physician Global Assessments for Disease Activity in Rheumatoid Arthritis Are All over the Map!
Matthew Turk¹ and Janet E. Pope², ¹Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada
Background/Purpose: Assessments of disease activity in rheumatoid arthritis (RA) determine the course of treatment. Physician global assessments of disease activity (MD globals) are important outcomes…
Abstract Number: 1511 • 2017 ACR/ARHP Annual Meeting
Real-Life Performance of the ASAS Health Index in Routine Care of Patients with Spondyloarthritis
Uta Kiltz, Thomas Wiatr, Xenofon Baraliakos, Kirill Fedorov and Jürgen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: The ASAS Health Index (ASAS HI) have been developed to measure health and impairment in functioning in patients with spondyloarthritis (SpA). Its measurement properties…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].